Product Description
An orally bioavailable, synthetic, small-molecule multi-Aurora kinase inhibitor with potential antineoplastic activity. Cenisertib selectively binds to and inhibits multiple Aurora kinases (AKs), which may result in the inhibition of cell division and proliferation, and the induction of apoptosis in tumor cells that overexpress AKs.
Mechanisms of Action: AURK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EMD Serono
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Pancreatic Cancer|Oncology Unspecified|Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01097512 | P1 |
Completed |
Pancreatic Cancer |
2010-07-01 |
|
NCT00391521 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-06-01 |
|
NCT01080664 | P1 |
Terminated |
Oncology Unspecified|Oncology Hematological Unspecified |
2010-03-01 |